Terns Pharmaceuticals Net Income
| TERN Stock | USD 38.19 0.21 0.55% |
As of the 11th of February 2026, Terns Pharmaceuticals has the Semi Deviation of 2.51, risk adjusted performance of 0.1778, and Coefficient Of Variation of 473.46. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Terns Pharmaceuticals, as well as the relationship between them.
Terns Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Terns Pharmaceuticals' valuation are provided below:Gross Profit | Market Capitalization | Enterprise Value Revenue 337.4686 | Revenue | Earnings Share (1.02) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -80 M | -84 M | |
| Net Loss | -54.3 M | -57 M | |
| Net Loss | -80 M | -84 M | |
| Net Loss | (1.01) | (1.06) | |
| Net Income Per E B T | 0.90 | 0.80 |
Terns | Net Income | Build AI portfolio with Terns Stock |
Evaluating Terns Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Terns Pharmaceuticals's fundamental strength.
Latest Terns Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Terns Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Terns Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Terns Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Terns Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Terns Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (88.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Terns Net Income Regression Statistics
| Arithmetic Mean | (41,827,634) | |
| Coefficient Of Variation | (71.51) | |
| Mean Deviation | 27,002,982 | |
| Median | (17,711,000) | |
| Standard Deviation | 29,909,785 | |
| Sample Variance | 894.6T | |
| Range | 72.5M | |
| R-Value | (0.87) | |
| Mean Square Error | 235.4T | |
| R-Squared | 0.75 | |
| Slope | (5,140,813) | |
| Total Sum of Squares | 14313.5T |
Terns Net Income History
Other Fundumenentals of Terns Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Terns Pharmaceuticals Net Income component correlations
Terns Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Terns Pharmaceuticals is extremely important. It helps to project a fair market value of Terns Stock properly, considering its historical fundamentals such as Net Income. Since Terns Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Terns Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Terns Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Terns diversify its offerings? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Terns Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Terns Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Terns Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Terns Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Terns Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Terns Pharmaceuticals or generate 0.0% return on investment in Terns Pharmaceuticals over 90 days. Terns Pharmaceuticals is related to or competes with Oric Pharmaceuticals, Precigen, Immatics, Enliven Therapeutics, Amylyx Pharmaceuticals, Nektar Therapeutics, and Relay Therapeutics. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combin... More
Terns Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Terns Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Terns Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.18 | |||
| Information Ratio | 0.1961 | |||
| Maximum Drawdown | 43.41 | |||
| Value At Risk | (5.58) | |||
| Potential Upside | 8.22 |
Terns Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Terns Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Terns Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Terns Pharmaceuticals historical prices to predict the future Terns Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1778 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 0.6518 | |||
| Sortino Ratio | 0.3777 | |||
| Treynor Ratio | (6.55) |
Terns Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1778 | |||
| Market Risk Adjusted Performance | (6.54) | |||
| Mean Deviation | 3.96 | |||
| Semi Deviation | 2.51 | |||
| Downside Deviation | 3.18 | |||
| Coefficient Of Variation | 473.46 | |||
| Standard Deviation | 6.13 | |||
| Variance | 37.56 | |||
| Information Ratio | 0.1961 | |||
| Jensen Alpha | 1.3 | |||
| Total Risk Alpha | 0.6518 | |||
| Sortino Ratio | 0.3777 | |||
| Treynor Ratio | (6.55) | |||
| Maximum Drawdown | 43.41 | |||
| Value At Risk | (5.58) | |||
| Potential Upside | 8.22 | |||
| Downside Variance | 10.13 | |||
| Semi Variance | 6.28 | |||
| Expected Short fall | (5.06) | |||
| Skewness | 3.22 | |||
| Kurtosis | 17.01 |
Terns Pharmaceuticals Backtested Returns
Terns Pharmaceuticals is not too volatile given 3 months investment horizon. Terns Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.19, which indicates the firm had a 0.19 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.2% are justified by taking the suggested risk. Use Terns Pharmaceuticals Risk Adjusted Performance of 0.1778, coefficient of variation of 473.46, and Semi Deviation of 2.51 to evaluate company specific risk that cannot be diversified away. Terns Pharmaceuticals holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of -0.2, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Terns Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Terns Pharmaceuticals is likely to outperform the market. Use Terns Pharmaceuticals potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Terns Pharmaceuticals.
Auto-correlation | -0.59 |
Good reverse predictability
Terns Pharmaceuticals has good reverse predictability. Overlapping area represents the amount of predictability between Terns Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Terns Pharmaceuticals price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Terns Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.59 | |
| Spearman Rank Test | -0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 4.55 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Terns Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Terns Pharmaceuticals reported net income of (88.85 Million). This is 126.04% lower than that of the Pharmaceuticals sector and 226.85% lower than that of the Health Care industry. The net income for all United States stocks is 115.56% higher than that of the company.
Terns Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Terns Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics of similar companies.Terns Pharmaceuticals is currently under evaluation in net income category among its peers.
Terns Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Terns Pharmaceuticals from analyzing Terns Pharmaceuticals' financial statements. These drivers represent accounts that assess Terns Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Terns Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 461.5M | 462.1M | 178.7M | 366.8M | 421.8M | 420.2M | |
| Enterprise Value | 449.2M | 400.1M | 131.0M | 224.8M | 258.5M | 343.9M |
Terns Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Terns Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Terns Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Terns Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Terns Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Terns Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Terns Pharmaceuticals' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 1.6 M | State Street Corp | 2025-06-30 | 1.4 M | Superstring Capital Management Lp | 2025-06-30 | 1.3 M | Adage Capital Partners Gp Llc | 2025-06-30 | 1.3 M | Franklin Resources Inc | 2025-06-30 | 1.3 M | Nuveen, Llc | 2025-06-30 | 1.2 M | Ubs Group Ag | 2025-06-30 | 1.2 M | Millennium Management Llc | 2025-06-30 | 996.8 K | Renaissance Technologies Corp | 2025-06-30 | 922.5 K | Soleus Capital Management, L.p. | 2025-06-30 | 8.2 M | Orbimed Advisors, Llc | 2025-06-30 | 7.6 M |
Terns Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 3.84 B | ||||
| Shares Outstanding | 108.77 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 85.80 % | ||||
| Number Of Shares Shorted | 16.15 M | ||||
| Price To Book | 14.54 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (100.97 M) | ||||
| Net Income | (88.85 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 1.35 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 3.25 X | ||||
| Cash Flow From Operations | (70.02 M) | ||||
| Short Ratio | 5.96 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Target Price | 58.11 | ||||
| Number Of Employees | 59 | ||||
| Beta | -0.28 | ||||
| Market Capitalization | 4.13 B | ||||
| Total Asset | 363.93 M | ||||
| Retained Earnings | (421.48 M) | ||||
| Working Capital | 346.46 M | ||||
| Net Asset | 363.93 M |
About Terns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Terns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Terns Stock
| 0.59 | PSGTF | PT Semen Indonesia | PairCorr |
| 0.36 | MSFT | Microsoft Sell-off Trend | PairCorr |
| 0.32 | HPQ | HP Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Pharmaceuticals sector continue expanding? Could Terns diversify its offerings? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Terns Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.